# OrphanCure Full Pipeline Report: repodb_0ee62470d8ffb2ae

- Drug: Cisplatin
- Disease: Esophageal neoplasm metastatic
- Mode: no_verifier
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Cisplatin is a standard treatment for advanced esophageal cancer, but resistance is a significant challenge. Several studies investigate mechanisms of cisplatin resistance in esophageal cancer, focusing on miRNAs, lncRNAs, and specific genes like FAM111B and ZCCHC4. While cisplatin is established in treatment, repurposing efforts would need to address or overcome these resistance mechanisms.",
      "evidence_counts": {
        "total_papers": 59,
        "supporting": 43,
        "contradicting": 6,
        "inconclusive": 10
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose CISPLATIN for esophageal cancer",
      "drug": {
        "id": "CHEMBL11359",
        "name": "CISPLATIN",
        "aliases": [
          "cis-diamminedichloroplatinum(II)",
          "cis-DDP",
          "DDP",
          "cisplatin",
          "CDDP"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0007576",
        "name": "esophageal cancer",
        "aliases": [
          "cancer of the esophagus",
          "esophageal carcinoma",
          "esophageal neoplasm",
          "malignancy of esophagus",
          "esophageal tumor"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 59,
      "polarity": {
        "supports": 43,
        "contradicts": 6,
        "inconclusive": 10
      },
      "support_ratio": "43 of 59 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "38494800",
          "title": "[History and Perspective of Chemotherapy in Advanced Esophageal Cancer].",
          "year": "2024",
          "relevance_score": 11.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "36995552",
          "title": "NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells.",
          "year": "2023",
          "relevance_score": 10.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "31267531",
          "title": "microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPAR\u03b3 in esophageal cancer.",
          "year": "2020",
          "relevance_score": 10.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "37672204",
          "title": "Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.",
          "year": "2024",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "34277424",
          "title": "Downregulation of miR-135b-5p Suppresses Progression of Esophageal Cancer and Contributes to the Effect of Cisplatin.",
          "year": "2021",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "37401860",
          "title": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
          "year": "2023",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "39934309",
          "title": "ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "40269355",
          "title": "Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "33644048",
          "title": "Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.",
          "year": "2021",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Clinical study"
          ]
        },
        {
          "pmid": "40275604",
          "title": "Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "Medium",
        "literature_strength": "High",
        "clinical_evidence": "High"
      },
      "quality_scorecard": {
        "overall_score": 0.787,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "4/4 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "15 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/4 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "4/4 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Cisplatin resistance is a significant clinical challenge.",
        "Toxicity of cisplatin needs careful management."
      ],
      "limitations": [
        "The provided literature primarily focuses on mechanisms of cisplatin resistance rather than direct evidence for repurposing beyond established use.",
        "Lack of randomized controlled trials for cisplatin-based regimens in advanced esophageal cancer is noted.",
        "The summary of papers (supporting, contradicting, inconclusive) is not fully detailed in the provided abstracts."
      ],
      "missing_data": [
        "Direct evidence of cisplatin repurposing for esophageal cancer beyond its current standard use.",
        "Detailed comparative efficacy studies of cisplatin versus other agents in esophageal cancer.",
        "Information on specific patient populations that might benefit most from cisplatin therapy."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies to overcome cisplatin resistance mechanisms.",
        "Explore novel biomarkers for predicting response to cisplatin-based therapy.",
        "Conduct clinical trials evaluating cisplatin in specific patient subgroups or in combination with emerging therapies."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 4,
      "claims": [
        {
          "claim_id": "CLM-64b2c1",
          "statement": "Cisplatin is a standard treatment for advanced esophageal cancer.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 3,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-23f92e",
          "statement": "Cisplatin resistance is a major challenge in esophageal cancer treatment.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-c7340f",
          "statement": "MicroRNAs (miRNAs) are implicated in cisplatin resistance in esophageal cancer.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-2189d8",
          "statement": "Specific genes and pathways are involved in cisplatin resistance in esophageal cancer.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 4,
      "entries": [
        {
          "claim_id": "CLM-64b2c1",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "7fa2ac9caab4",
          "timestamp": "2026-06-03T14:29:38.950490+00:00",
          "paper_evidence": [
            {
              "pmid": "38494800",
              "snippet": "CF(cisplatin plus 5-FU)therapy and taxanes( paclitaxel or docetaxel)were considered standard treatments for first- and second-line treatment of advanced esophageal carcinoma based on the results of ph",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37672204",
              "snippet": "Chemotherapeutic agents such as cisplatin are commonly used in patients with clinically unresectable or recurrent esophageal cancer (ESCA).",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "Cisplatin (CDDP) is a conventional chemotherapy drug.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-23f92e",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "7fa2ac9caab4",
          "timestamp": "2026-06-03T14:29:38.950490+00:00",
          "paper_evidence": [
            {
              "pmid": "36995552",
              "snippet": "Resistance to cisplatin, one of the majorly used chemotherapeutic drugs in EC, is a major nuisance.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37672204",
              "snippet": "However, patients often develop resistance to cisplatin, which in turn leads to a poor prognosis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "However, the acquired cisplatin resistance limits its extensively clinical applications.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "40269355",
              "snippet": "Cisplatin (DDP) resistance is a key factor hindering esophageal cancer (ESCA) treatment.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-c7340f",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "7fa2ac9caab4",
          "timestamp": "2026-06-03T14:29:38.950490+00:00",
          "paper_evidence": [
            {
              "pmid": "36995552",
              "snippet": "This study sheds light on miRNA dysregulation and its inverse relation with dysregulated mRNAs to guide pathways into the manifestation of cisplatin resistance in EC.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "31267531",
              "snippet": "It is reported that microRNAs (miRNAs) are implicated in chemotherapy resistance of various malignancies. miR-10b was previously proved as an oncogene in multiple malignancies, including esophageal ca",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "34277424",
              "snippet": "MicroRNAs (miRNAs) play a pivotal role in various cancers, including EC. Our research aimed to reveal the function and mechanism of miR-135b-5p. Our research identified that miR-135b-5p was elevated i",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-2189d8",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "7fa2ac9caab4",
          "timestamp": "2026-06-03T14:29:38.950490+00:00",
          "paper_evidence": [
            {
              "pmid": "37672204",
              "snippet": "Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "39934309",
              "snippet": "ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "40269355",
              "snippet": "Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        }
      ]
    }
  },
  "metadata": {
    "run_id": "7fa2ac9caab4",
    "created_at": "2026-06-03T14:29:14.973075+00:00",
    "drug": "CISPLATIN",
    "disease": "esophageal cancer",
    "total_claims": 4,
    "quality_score": 0.7875,
    "reruns": 0
  }
}
```
